Harpoon Therapeutics Presents Preclinical Data for HPN328, a DLL3-targeting T Cell Engager, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 29, 2019 12:30 ET
|
Harpoon Therapeutics
HPN328, a TriTAC®, Exhibits the Potency, Tolerability, and Pharmacokinetics to Support Initiation of Clinical Development in 2020 SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) --...
Harpoon Therapeutics Announces Presentation on HPN328 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 22, 2019 16:05 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...